Diclofenac Sodium Suppositories 25mg for Rectal Insertion 5 Suppositories

Product Details
Customization: Available
Application: Paediatrics
Usage Mode: For external use
Gold Member Since 2014

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Years of Export Experience
The export experience of the supplier is more than 10 years
High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
Importers and Exporters
The supplier has import and export rights
to see all verified strength labels (11)
  • Diclofenac Sodium Suppositories 25mg for Rectal Insertion 5 Suppositories
  • Diclofenac Sodium Suppositories 25mg for Rectal Insertion 5 Suppositories
  • Diclofenac Sodium Suppositories 25mg for Rectal Insertion 5 Suppositories
  • Diclofenac Sodium Suppositories 25mg for Rectal Insertion 5 Suppositories
  • Diclofenac Sodium Suppositories 25mg for Rectal Insertion 5 Suppositories
Find Similar Products

Basic Info.

Model NO.
25mg
Suitable for
Children, Adult
State
Solid
Shape
Tablet
Type
Biological Products
Pharmaceutical Technology
Chemical Synthesis
Function
Relieve Fever
Pharmaceutical Form
Suppositories
Transport Package
as Your Request
Specification
25mg
Trademark
No
Origin
China
HS Code
3004909099
Production Capacity
60, 000, 000 Pieces/Year

Product Description

Diclofenac Sodium Suppositories 25mg for Rectal Insertion 5 SuppositoriesDiclofenac Sodium Suppositories 25mg for Rectal Insertion 5 SuppositoriesDiclofenac Sodium Suppositories 25mg for Rectal Insertion 5 SuppositoriesDiclofenac Sodium Suppositories 25mg for Rectal Insertion 5 Suppositories
 

The active substance is sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate (diclofenac sodium).

Each suppository contains 25mgdiclofenac sodium Ph.Eur.
 
Therapeutic indications

Diclofenac sodium 25mg suppositories

Adults and Elderly:

Relief of all grades of pain and inflammation in a wide range of conditions, including:

(i)

arthritic conditions: rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout,

 

(ii)

acute musculo-skeletal disorders such as periarthritis (for example frozen shoulder), tendinitis, tenosynovitis, bursitis,

(iii)

other painful conditions resulting from trauma, including fracture, low back pain, sprains, strains, dislocations, orthopaedic, dental and other minor surgery.

 

Children (aged 1-12 years): Juvenile chronic arthritis

Children (aged 6 years and above): As monotherapy or as adjunct therapy with other opiates (due to its opiate-sparing effect) for the relief of acute post-operative pain.

Posology and method of administration

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4 Special warnings and precautions for use).

Not to be taken by mouth, as per rectal administration only.

The suppositories should be inserted well into the rectum. It is recommended to insert the suppositories after passing stools.

Adults:

75-150mg daily, in divided doses (25mg, 50mg and 100mg suppositories only).

 

The recommended maximum daily dose of Voltarol is 150mg. This may be administered using a combination of dosage forms, e.g. tablets and suppositories. (25mg and 50mg suppositories only).

100mg suppositories may also be given as a once daily treatment, usually at night. Where necessary, therapy may be combined with 25mg or 50mg tablets or suppositories up to the maximum dose of 150mg per day.

Special populations

Elderly

Although the pharmacokinetics of Voltarol are not impaired to any clinically relevant extent in elderly patients, nonsteroidal anti-inflammatory drugs should be used with particular caution in such patients who generally are more prone to adverse reactions. In particular it is recommended that the lowest effective dosage be used in frail elderly patients or those with a low body weight (see also Precautions) and the patient should be monitored for GI bleeding during NSAID therapy.

Cardiovascular and significant cardiovascular risk factors

Diclofenac is contraindicated in patients with established congestive heart failure (NYHA II-IV), ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease .

Patients with congestive heart failure (NYHA-I) or significant risk factors for cardiovascular disease should be treated with diclofenac only after careful consideration. Since cardiovascular risks with diclofenac may increase with dose and duration of exposure, the lowest effective daily dose should be used and for the shortest duration possible (see section 4.4 Special warnings and precautions for use)

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier